CN103127061A - Medicine application of chloranthus japonicus alcohol M - Google Patents
Medicine application of chloranthus japonicus alcohol M Download PDFInfo
- Publication number
- CN103127061A CN103127061A CN2011103869848A CN201110386984A CN103127061A CN 103127061 A CN103127061 A CN 103127061A CN 2011103869848 A CN2011103869848 A CN 2011103869848A CN 201110386984 A CN201110386984 A CN 201110386984A CN 103127061 A CN103127061 A CN 103127061A
- Authority
- CN
- China
- Prior art keywords
- alcohol
- cell
- herba chloranthi
- chloranthi japonici
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the fields of chemical industry and medicine, and relates to an application of chloranthus japonicus alcohol M in preparation of anti-neoplastic drugs. The invention provides the application of the chloranthus japonicus alcohol M in preparation of the anti-neoplastic drugs. Cancer cells comprise hepatoma carcinoma cells, cervical cancer cells, leucocythemia cells, and pancreatic cancer cells. The chloranthus japonicus alcohol M belongs to a natural product, is low in toxic side-effect, high in bioavailability, and stable in property, and has clinical use value. A small molecule compound of the chloranthus japonicus alcohol M is used as a novel anti-neoplastic drug or an auxiliary element of the novel anti-neoplastic drug to be developed, tumor suppression effect is obvious, green environmental protection is achieved, and a novel method and a novel means are supplied for tumour treatment and cure.
Description
Technical field
The invention belongs to chemical field and field of medicaments, relate to the application of Herba chloranthi japonici alcohol M in the preparation antitumor drug.
Background technology
Herba chloranthi japonici is herb or the root and rhizome of Chloranthaceae plant Herba chloranthi japonici (Chloranthus Japonicus Sieb).Sesquiterpenoids is a compounds important in the Chloranthaceae plant, in whole Chloranthaceae plant, distribution is arranged all, has the biological activitys such as antiinflammatory spasmolytic, inhibition microorganism.Obtain half its skeleton of terpenoid complex structure in Herba chloranthi japonici and can be divided into a few types such as eudesmane type, ring eudesmane-type, germacrane, acorane type, they have the various ways such as lactone, ketone, alcohol, polymer simultaneously.
Herba chloranthi japonici alcohol M, its structural formula is as follows:
2008, Wang etc. have extracted Herba chloranthi japonici alcohol M from silk fringe chu lan tree, and resolved in detail its structure (compound 3, Lindenane Sesquiterpene Dimers from Chloranthus fortunei., Journal of Natural Products, 71 (4), 674-677., 2008).But the research report about its function is less.
Herba chloranthi japonici alcohol M is natural product, and bioavailability is higher, character is more stable, has clinical use value.To going deep into that the chemistry and biology of this compounds is studied, its molecular mechanism of action will be progressively clear and definite along with people, and this chemical constitution that will further promote this compounds is modified and structure activity study, and helps to improve the medical value of this compounds.
Summary of the invention
The medicinal usage that the purpose of this invention is to provide Herba chloranthi japonici alcohol M.
The invention provides the application of Herba chloranthi japonici alcohol M in the preparation antitumor drug.Described antitumor drug can be the medicine of anti-hepatocarcinoma, leukemia, cancer of pancreas or cervical cancer.This antitumor drug can be injection or tablet.
The invention provides a kind of method that suppresses tumor cell in vitro propagation, Herba chloranthi japonici alcohol M is added in the culture fluid of tumor cell.Described tumor cell can be hepatoma carcinoma cell, blood cell, cervical cancer cell, lung adenocarcinoma cell or pancreatic cancer cell.The hepatoma carcinoma cell that adopts in one embodiment of the present of invention is QGY and HepG2.Generally speaking, adding the final concentration of Herba chloranthi japonici alcohol M is 0.1-50 μ M.For example, 0.1-5 μ M, 0.1-10 μ M, 0.1-1 μ M, 0.1-20 μ M, 1-12 μ M, 1-20 μ M, 1-50 μ M, 0.2-36 μ M, 0.2-16 μ M, 10-40 μ M, 0.2-12 μ M, 10-15 μ M, 10-20 μ M, 10-30 μ M, 10-50 μ M, 15-50 μ M, etc.
The present invention also provides a kind of antitumor drug, and the active component of described antitumor drug is Herba chloranthi japonici alcohol M.Described tumor can be hepatocarcinoma, cancer of pancreas, cervical cancer or leukemia.
Micromolecular compound of the present invention can adopt the preparation method preparation of various routines.For example, adopt the synthetic method of artificial chemistry.
Utilize micromolecular compound of the present invention, by various conventional screening techniques, can filter out and the interactional material of Herba chloranthi japonici alcohol M generation, as receptor, inhibitor or antagonist etc.
The present invention and inhibitor, antagonist etc. when using (administration) in treatment, can provide different effects.Usually, these materials can be formulated in nontoxic, inertia with pharmaceutically acceptable aqueous carrier medium in, wherein pH is about 5-8 usually, preferably pH is about 6-8, pH value can change to some extent with the character that is formulated material and disease to be treated.The pharmaceutical composition for preparing can carry out administration by conventional route, comprising (but being not limited to): intramuscular, intraperitoneal, subcutaneous, Intradermal or topical.
Take Herba chloranthi japonici of the present invention alcohol M as example, can be with itself and suitable pharmaceutically acceptable carrier coupling.This class pharmaceutical composition contains compound and pharmaceutically acceptable carrier or the excipient for the treatment of effective dose.This class carrier comprises (but being not limited to): saline, buffer, glucose, water, glycerol, ethanol and combination thereof.Pharmaceutical preparation should be complementary with administering mode.Herba chloranthi japonici of the present invention alcohol M can be made into the injection form, for example with normal saline or contain glucose and the aqueous solution of other adjuvant is prepared by conventional method.Pharmaceutical composition such as Tablet and Capsula can be prepared by conventional method.Pharmaceutical composition such as injection, solution, Tablet and Capsula should be made under aseptic condition.The dosage of active component is the treatment effective dose, for example every day about 5 mg/kg body weight of 1 microgram/kg body weight-Yue.In addition, Herba chloranthi japonici alcohol M of the present invention also can use together with the other treatment agent.
When Herba chloranthi japonici alcohol M of the present invention is used as medicine, the Herba chloranthi japonici alcohol M for the treatment of effective dose can be applied to mammal, wherein should treat effective dose usually at least about 10 micrograms/kg body weight, and in most of the cases be no more than approximately 8 mg/kg body weight, preferably this dosage is the about 1 mg/kg body weight of 10 micrograms/kg body weight-Yue.Certainly, concrete dosage also should be considered the factors such as route of administration, patient health situation, and these are all within the skilled practitioners skill.
The invention provides the application of Herba chloranthi japonici alcohol M in the preparation antitumor drug.Herba chloranthi japonici alcohol M is natural product, and side effect is less, obviously the propagation of inhibition tumor cell.Micromolecular compound of the present invention is developed as new antitumor drug or its auxiliary element, and tumor killing effect is obvious, environmental protection, and will and cure tumor for treatment provides a kind of new approach and means.
The specific embodiment
Experimental technique:
1. cell recovery
1) take out cryopreservation tube from liquid nitrogen container, directly drop in 37 ℃ of warm water, and frequently shake and make it melt as early as possible.
2) take out cryopreservation tube from 37 ℃ of water-baths, with suction pipe sucking-off cell suspension, inject centrifuge tube and add culture fluid more than 10 times, low-speed centrifugal after mixing is abandoned supernatant, then is repeated to wash once with culture fluid.
3) with after the suitable dilution of culture fluid, the inoculated and cultured bottle is placed on 37 ℃ of standing cultivations of incubator, changes culture fluid next day, continues to cultivate.Go down to posterity when being cultured to finite concentration.The PANC-1 cell culture is in containing the DMEM high glucose medium of 10%Gibico hyclone, and HELA, QGY and HepG2 cell culture contain 100U/ml penicillin and 100 μ g/ml streptomycins in culture medium in containing the DMEM high glucose medium of 10% hyclone.
2. passage is cultivated
The situation of observation of cell growth every day is grown to approximately 90% and is gone down to posterity when converging in culture bottle when cell, approximately went down to posterity once every 2-4 days.One bottle goes down to posterity into three bottles, or a 25cm
2Go down to posterity in a 75cm
2Culture bottle in.Method:
1) with 1 * phosphate buffer washed cell once.
2) add 2-3ml trypsinization liquid digestion, be placed in 37 ℃ of incubator numbers minute.Pat Tissue Culture Flask with hands, make cell separation.
3) suitable culture medium with the Gibico hyclone that contains 10-15% stops trypsinization.Cell is sub-packed in new culture bottle, continues to cultivate.
3. cell cryopreservation
1) get the cell tryptase protease digestion that is cultured to exponential phase, be collected in centrifuge tube and counting, centrifugal.
2) reject trypsin and old culture fluid add the frozen culture fluid (containing 10%DMSO, 40%DMEM and 50%Gibico hyclone) that configures, and in cryopreserving liquid, the ultimate density of cell is 0.5-1 * 10
7/ ml.Blow and beat gently with suction pipe and make cell even, then be distributed in aseptic cryopreservation tube, every pipe adds 1-1.5ml.
3) cryopreservation tube is put into freezing storing box and put-80 ℃ of quick-freezings, move in liquid nitrogen container after 5 hours and preserve.
4. medicine is prepared:
Herba chloranthi japonici alcohol M is dissolved in DMSO (dimethyl sulfoxide), and the mother solution that is mixed with 100mM or 50mM is standby.
Embodiment 1MTS method is measured Herba chloranthi japonici alcohol M to the growth inhibited effect of hepatoma carcinoma cell
HepG2 (available from ATCC) 3 * 10
3/ hole is seeded to 96 orifice plates, cultivates to make it to add after adherent Herba chloranthi japonici alcohol M (available from Shanghai Pharmaceutical Inst., Chinese Academy of Sciences) in 24 hours, establishes 6 Concentraton gradient, and each concentration is established 3 multiple holes.Cell is at 37 ℃, 5%CO
2Cultivate after 72 hours under condition, outwell culture fluid, measure cell survival rate with MTS test kit (Promega company).
Method of testing is: cell is washed one time with serum-free medium, added the MTS chromophoric solution (adding 2ml solution 1 and 100 μ l solution 2 in the 10ml serum-free medium, fully mixing) for preparing in advance according to the amount of 100 μ l/well.Do not have the hole of cell to be made as this bottom outlet with one, absorb in order to the bias light of calibration solution.Cell is put into cell culture incubator to be continued to cultivate 2～4 hours, then read absorbance value (reference wavelength 630-700nm with microplate reader, measure wavelength 490nm), calculate cell survival rate, to measure hole absorbance value/control wells absorbance value as the numerical value of cell survival rate.According to cell survival rate, calculate Herba chloranthi japonici alcohol M to the IC50 value of HepG2 cell.
IC50 refers to the concentration of a suppressed half inhibitor.Here be the HepG2 cell quantity and be the concentration of a half Herba chloranthi japonici alcohol M of contrast.The calculating of IC50 generally need to be measured the dosage effect more than 5, then obtains function calculation by curve fitting and get.
Result: Herba chloranthi japonici alcohol M is 35.84 μ M to the IC50 value of HepG2 cell.
The test QGY cell (available from Chinese Academy of Sciences's cell bank) that uses the same method, Herba chloranthi japonici alcohol M is about 0.92 μ M to the IC50 value of SMMC-7721 cell as a result.
The growth inhibited effect of embodiment 2 Herba chloranthi japonici alcohol M to human pancreatic cancer cell
Utilize cck-8 test kit (Japanese colleague's chemistry institute) to detect.
Step:
1) PANC-1 cell (available from Chinese Academy of Sciences's cell bank) is planted in 96 orifice plates uniformly, every porocyte number is 3 * 10
3Individual.
2) treat adherent, the rear dosing of spending the night, dosing (Herba chloranthi japonici alcohol M concentration be respectively 50,16.67,5.56,1.85,0.62 μ M), each concentration has 3 multiple holes.
3) cultivated 48 hours, complete medium is replaced to the mixture (10: 1) of serum-free medium and CCK8, hatched 2 hours in 37 ℃ of incubators.
4) take 450nm as measuring wavelength, take 650nm as the contrast wavelength, measure reading on microplate reader.
Result: Herba chloranthi japonici alcohol M is 11.05 μ M to the IC50 value of PANC-1 cell.
The growth inhibited effect of embodiment 3 Herba chloranthi japonici alcohol M to the human leukemia cell
Method according to embodiment 2 detects Herba chloranthi japonici alcohol M to the effect of K562 cell, and result shows that Herba chloranthi japonici alcohol M is 15.83 μ M to the IC50 value of K562 cell.
The growth inhibited effect of embodiment 4 Herba chloranthi japonici alcohol M to human lung adenocarcinoma cell
Method according to embodiment 2 detects Herba chloranthi japonici alcohol M to the effect of A549 cell, and result shows that Herba chloranthi japonici alcohol M is 705 μ M to the IC50 value of A549 cell.
The growth inhibited effect of embodiment 5 Herba chloranthi japonici alcohol M to human cervical carcinoma cell
Method according to embodiment 2 detects Herba chloranthi japonici alcohol M to the effect of HELA cell, and result shows that Herba chloranthi japonici alcohol M is 0.20 μ M to the IC50 value of HELA cell.
Claims (11)
1. the application of Herba chloranthi japonici alcohol M in the preparation antitumor drug.
2. application as claimed in claim 1, is characterized in that, described tumor is hepatocarcinoma, cervical cancer, leukemia or cancer of pancreas.
3. application as claimed in claim 1, is characterized in that, described antitumor drug is medicines resistant to liver cancer.
4. application as claimed in claim 1, is characterized in that, described antitumor drug is anti-cancer of pancreas medicine.
5. application as claimed in claim 1, is characterized in that, the dosage form of described antitumor drug is injection, tablet or capsule.
6. a method that suppresses tumor cell in vitro propagation, is characterized in that, Herba chloranthi japonici alcohol M is added in the culture fluid of tumor cell.
7. method as claimed in claim 6, is characterized in that, described tumor cell is hepatoma carcinoma cell, cervical cancer cell, leukaemia or pancreatic cancer cell.
8. method as claimed in claim 6, is characterized in that, adding the final concentration of Herba chloranthi japonici alcohol M is 0.1-50 μ M.
9. method as claimed in claim 6, is characterized in that, adding the final concentration of Herba chloranthi japonici alcohol M is 1-15 μ M.
10. an antitumor drug, is characterized in that, the active component of described antitumor drug is Herba chloranthi japonici alcohol M.
11. antitumor drug as claimed in claim 10 is characterized in that, described tumor is hepatocarcinoma, cervical cancer, leukemia or cancer of pancreas.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011103869848A CN103127061A (en) | 2011-11-28 | 2011-11-28 | Medicine application of chloranthus japonicus alcohol M |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011103869848A CN103127061A (en) | 2011-11-28 | 2011-11-28 | Medicine application of chloranthus japonicus alcohol M |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103127061A true CN103127061A (en) | 2013-06-05 |
Family
ID=48487936
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011103869848A Pending CN103127061A (en) | 2011-11-28 | 2011-11-28 | Medicine application of chloranthus japonicus alcohol M |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103127061A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105213369A (en) * | 2014-07-03 | 2016-01-06 | 复旦大学 | Shizukaol D is preparing the application in Hepatoma therapy medicine |
| CN105267206A (en) * | 2014-07-03 | 2016-01-27 | 复旦大学 | Application of ShizukaolD in preparing medicine for inhibiting clone formation of hepatoma carcinoma cells |
| CN107865865A (en) * | 2016-09-23 | 2018-04-03 | 中国科学院上海药物研究所 | Purposes of a kind of onoseriolide Dimerized sesquiterpenoids in antimalarial agent is prepared |
-
2011
- 2011-11-28 CN CN2011103869848A patent/CN103127061A/en active Pending
Non-Patent Citations (3)
| Title |
|---|
| CHUANG-JUN LI ET AL.: "Bis-sesquiterpenes and diterpenes from Chloranthus henryi", 《PHYTOCHEMISTRY》 * |
| XIA-CHANG WANG ET AL.: "Lindenane Sesquiterpene Dimers from Chloranthus fortunei", 《JOURNAL OF NATURAL PRODUCTS》 * |
| XIU-FENG HE ET AL.: "Sesquiterpenes and Dimeric Sesquiterpenoids from Sarcandra glabra.", 《JOURNAL OF NATRUAL PRODUCTS》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105213369A (en) * | 2014-07-03 | 2016-01-06 | 复旦大学 | Shizukaol D is preparing the application in Hepatoma therapy medicine |
| CN105267206A (en) * | 2014-07-03 | 2016-01-27 | 复旦大学 | Application of ShizukaolD in preparing medicine for inhibiting clone formation of hepatoma carcinoma cells |
| CN105213369B (en) * | 2014-07-03 | 2018-07-24 | 复旦大学 | Shizukaol D is preparing the application in treating liver-cancer medicine |
| CN107865865A (en) * | 2016-09-23 | 2018-04-03 | 中国科学院上海药物研究所 | Purposes of a kind of onoseriolide Dimerized sesquiterpenoids in antimalarial agent is prepared |
| CN107865865B (en) * | 2016-09-23 | 2020-02-11 | 中国科学院上海药物研究所 | Application of lindane dimeric sesquiterpene compound in preparation of antimalarial drugs |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102526073A (en) | Application of mogrol H9 for preparing antitumor drugs | |
| CN103127060A (en) | Application of chloranthus japonicus alcohol D in preparation of antitumor drugs | |
| CN103127049A (en) | Application of usnic acid in manufacturing antitumor drugs | |
| CN103127061A (en) | Medicine application of chloranthus japonicus alcohol M | |
| CN103127063A (en) | Application of chloranthus japonicus alcohol F in preparation of antitumor drugs | |
| CN103202834A (en) | Applications of oridonin in the preparation of antineoplastic drugs | |
| CN102397280B (en) | Application of 2 alpha-hydroxy protopanoxadiol medicine | |
| CN103417536B (en) | The application in antitumor drug prepared by harmol | |
| CN103099805A (en) | Application of isosteviol derivative H14 in preparation of antitumor medicaments | |
| CN103127062A (en) | Application of 13'-acetyl silver grass alcohol C in manufacturing of antineoplastic drugs | |
| CN102366416B (en) | Pharmaceutical application of 12-dehydroxy-21-hydroxy protopanoxadiol | |
| CN103054851A (en) | Application of chloranthalactone C in preparation of anti-tumor medicament | |
| CN103417527A (en) | Medical uses of methyl (E)-3-[2-(4-hydroxy-3-methoxyphenyl)-3-hydroxymethyl-7-methoxy-2,3-dihydro-1-benzofuran-5-yl]-prop-2-enoate | |
| CN104706649A (en) | Application of oroxyloside to preparation of anti-tumor drugs | |
| CN103127039A (en) | Application of magnolol in preparation of antitumor drug | |
| CN103127057A (en) | Application of fraxinellone in preparing of antineoplastic medicines | |
| CN102488677B (en) | Application of thelephora ganbajun in preparation of antitumor drugs | |
| CN103083330B (en) | Application of solasodine in preparing antitumor medicines | |
| CN103127103A (en) | Application of sophoridine in anti-tumor drug preparation | |
| CN103127051A (en) | Application of curcumenol in anti-tumor drug preparation | |
| CN103127056A (en) | Application of psoromic acid in anti-tumor drug preparation | |
| CN103099804A (en) | Application of isosteviol lactone in preparation of antitumor medicaments | |
| CN103083331B (en) | Application of solanum laciniatum ketene in preparing antitumor medicines | |
| CN103127102A (en) | Application of 8-propyl dicyan berberine in preparation of antitumor drug | |
| CN102366417A (en) | Application of protopanoxadiol in preparation of antitumor medicaments |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20130605 |